Table 26Summary evidence profile for fluoxetine + DBT versus placebo + DBT

OutcomeAnger (clinician- rated)Aggression (clinician- rated)Anxiety (clinician- rated)Depression (self-rated)Global functioningSelf-injury subscale of OASSuicidality subscale of OAS
Effect sizeSMD = −0.55 (−1.45, 0.35)*SMD = −0.59 (−1.5, 0.31)*SMD = 0.15 (−0.73, 1.03)SMD = 0.76 (−0.16, 1.68)*SMD = 0.06 (−0.82, 0.94)SMD = 0.03 (−0.85, 0.92)*SMD = 0.44 (−0.46, 1.33)*
Evidence qualityVery lowVery lowVery lowVery lowVery lowVery lowVery low
Number of studies/participants(K = 1; n = 20)(K = 1; n = 20)(K = 1; n = 20)(K = 1; n = 20)(K = 1; n = 20)(K = 1; n = 20)(K = 1; n = 20)
Forest plotCombo 02.01Combo 01.01Combo 03.01Combo 04.01Combo 04.02Combo 07.01Combo 07.01
*

Based on skewed data.

From: 5, PSYCHOLOGICAL AND PSYCHOSOCIAL TREATMENTS IN THE MANAGEMENT OF BORDERLINE PERSONALITY DISORDER

Cover of Borderline Personality Disorder
Borderline Personality Disorder: Treatment and Management.
NICE Clinical Guidelines, No. 78.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009.
Copyright © 2009, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.